FDA — authorised 7 April 2010
- Application: ANDA078414
- Marketing authorisation holder: OXFORD PHARMS
- Status: supplemented
FDA authorised 5 mg on 7 April 2010
Same drug, different regulators. Each page below lists the local marketing authorisation, HTA position, pricing, and adverse-event data.
Yes. FDA authorised it on 7 April 2010; FDA authorised it on 15 June 2010; FDA authorised it on 5 December 2023.
OXFORD PHARMS holds the US marketing authorisation.